Loading...
•
Mar 31, 2024
Alkermes Q1 2024 Earnings Report
Reported financial results for the first quarter of 2024, marking the first full quarter as a profitable, pure-play neuroscience company.
Key Takeaways
Alkermes reported a solid first quarter in 2024 with total revenues of $350.4 million and GAAP net income from continuing operations of $38.9 million. The company is advancing its strategic priorities, including LYBALVI's prescription growth and ALKS 2680's development.
Total revenues for the first quarter of 2024 were $350.4 million.
GAAP net income from continuing operations was $38.9 million, with diluted GAAP earnings per share from continuing operations at $0.23.
LYBALVI revenues grew 50% compared to the first quarter of 2023.
Alkermes is advancing ALKS 2680, a novel, investigational, oral orexin 2 receptor (OX2R) agonist, with phase 2 studies planned.
Revenue by Segment
Forward Guidance
Alkermes reiterates its financial expectations for 2024, as set forth in its press release dated Feb. 15, 2024.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...